//Краткое руководство по ведению пациентов с онкологическими заболеваниями мочеполовой системы

132//

recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006;65:965. https://www.ncbi.nlm.nih.gov/pubmed/16798415.

Beresford M.J. et al. A systematic review of the role of imaging before salvage radiotherapy for post-prostatectomy biochemical recurrence. Clin Oncol (R Coll Radiol). 2010;22:46. https://www.ncbi.nlm.nih.gov/pubmed/19948393.

Kane C.J. et al. Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy. Urology. 2003;61:607. https://www.ncbi.nlm.nih.gov/pubmed/12639656.

Evangelista L. et al. Choline PET or PET/CT and biochemical relapse of prostate cancer: a systematic review and meta-analysis. Clin Nucl Med. 2013;38:305. https://www.ncbi.nlm.nih.gov/pubmed/23486334.

Fuccio C. et al. Role of 11C-choline PET/CT in the re-staging of prostate cancer patients with biochemical relapse and negative results at bone scintigraphy. Eur J Radiol. 2012;81:e893. https://www.ncbi.nlm.nih.gov/pubmed/22621862.

Treglia G. et al. Relationship between prostate-specific antigen kinetics and detection rate of radiolabelled choline PET/CT in restaging prostate cancer patients: a meta-analysis. Clin Chem Lab Med. 2014;52:725. https://www.ncbi.nlm.nih.gov/pubmed/24310773.

Ceci F. et al. Impact of 11C-choline PET/CT on clinical decision making in recurrent prostate cancer: results from a retrospective two-centre trial. Eur J Nucl Med Mol Imaging. 2014;41:2222. https://www.ncbi.nlm.nih.gov/pubmed/25182750.

Scher H.I. et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008;26:1148. https://www.ncbi.nlm.nih.gov/pubmed/18309951.

Ryan C.J. et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368:138. https://www.ncbi.nlm.nih.gov/pubmed/23228172.

Fizazi K. et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised,

//Краткое руководство по ведению пациентов с онкологическими заболеваниями мочеполовой системы

//133

double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2012;13:983. https://www.ncbi.nlm.nih.gov/pubmed/22995653.

Beer T.M. et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371:424. https://www.ncbi.nlm.nih.gov/pubmed/24881730.

Scher H.I. et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367:1187. https://www.ncbi.nlm.nih.gov/pubmed/22894553.

Bahl A. et al. Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial. Ann Oncol. 2013;24:2402. https://www.ncbi.nlm.nih.gov/pubmed/23723295.

Костин А.А., Мурадян А.Г., Толкачев А.О., Попов С.В. Радий-223. Место в лечении метастатического кастрационно-рефрактерного рака предстатель-ной железы. Исследования и практика в медицине. 2017;4(4):79-88. doi: 10.17709/2409-2231-2017-4-4-9.